7 September 2020

Back British biotech by improving the clinical trials process

Andrew Boyle, CEO of LGB & Co. Limited, wrote an article for Pharmiweb on how to improve the British biotech sector.

The UK has a thriving life sciences sector. With three of the world’s top ten universities in the field – Oxford, Cambridge and UCL – plus prominent bioscience clusters in other British university cities such as Nottingham and Cardiff, UK research accounts for 12% of all life sciences academic citations worldwide (and nearly a fifth of the top 1% of these).

To read the full article, please click here.

Recent Articles

7 September 2020

Back British biotech by improving the clinical trials process

Andrew Boyle, CEO of LGB & Co. Limited, wrote an article for Pharmiweb on how to improve the British biotech sector.

Read more

News & Insights

1 September 2020

Is it safe to get back in the water? SME credit investments in the post-Covid world

Please join us to hear from our expert panel on how investors are viewing the market and assessing SME risk and resilience over the next 6 months and beyond. Read more

News & Insights

27 August 2020

COVID-19 is causing a renaissance in the UK biotech sector, we must ensure it lasts

Andrew Boyle, CEO of LGB & Co. Limited, wrote an article published in PharmaPhorum on the impact COVID-19 is having on the biotech sector in the UK.

Read more

News & Insights